Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Integra LifeSciences Expects Q3 Revenue of $410 Million to $412 Million

None

Integra LifeSciences (IART) said it expects preliminary third-quarter 2026 revenue of approximately $410 million to $412 million. The company said flooding at its Cincinnati facility negatively impacted third-quarter revenue by approximately $7 million.

Integra lowered its full-year 2026 revenue outlook to $1.634 billion to $1.654 billion and expects the Cincinnati supply disruption to reduce fourth-quarter revenue by approximately $15 million to $20 million.

  • Third-quarter adjusted diluted EPS is expected to be $0.55 to $0.59.
  • Full-year adjusted diluted EPS guidance was reduced to $2.30 to $2.40.
  • Third-quarter operating cash flow is expected to exceed $85 million.
  • Full-year operating cash flow is expected to be approximately $190 million to $200 million.
  • The company expects full manufacturing operations at the Cincinnati site to return during the second quarter of 2027.

$IART Hedge Fund Activity

We have seen 108 institutional investors add shares of $IART stock to their portfolio, and 83 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles